BACKGROUND: There is currently no reliable treatment for phantom limb pain (PLP). Chronic PLP and associated cortical abnormalities may be maintained from abnormal peripheral input, raising the possibility that a continuous peripheral nerve block (CPNB) of extended duration may permanently reorganize cortical pain mapping, thus providing lasting relief. METHODS:Three men with below-the-knee (2) or -elbow (1) amputations and intractable PLP received femoral/sciatic or infraclavicular perineural catheter(s), respectively. Subjects were randomized in a double-masked fashion to receive perineural ropivacaine (0.5%) or normal saline for over 6 days as outpatients using portable electronic infusion pumps. Four months later, subjects returned for repeated perineural catheter insertion and received an ambulatory infusion with the alternate solution ("crossover"). Subjects were followed for up to 1 year. RESULTS: By chance, all three subjects received saline during their initial infusion and reported little change in their PLP. One subject did not receive crossover treatment, but the remaining two subjects reported complete resolution of their PLP during and immediately following treatment with ropivacaine. One subject experienced no PLP recurrence through the 52-week follow-up period and the other reported mild PLP occurring once each week of just a small fraction of his original pain (pretreatment: continuous PLP rated 10/10; posttreatment: no PLP at baseline with average of one PLP episode each week rated 2/10) for 12 weeks (lost to follow-up thereafter). CONCLUSIONS: A prolonged ambulatory CPNB may be a reliable treatment for intractable PLP. The results of this pilot study suggest that a large, randomized clinical trial is warranted. Wiley Periodicals, Inc.
RCT Entities:
BACKGROUND: There is currently no reliable treatment for phantom limb pain (PLP). Chronic PLP and associated cortical abnormalities may be maintained from abnormal peripheral input, raising the possibility that a continuous peripheral nerve block (CPNB) of extended duration may permanently reorganize cortical pain mapping, thus providing lasting relief. METHODS: Three men with below-the-knee (2) or -elbow (1) amputations and intractable PLP received femoral/sciatic or infraclavicular perineural catheter(s), respectively. Subjects were randomized in a double-masked fashion to receive perineuralropivacaine (0.5%) or normal saline for over 6 days as outpatients using portable electronic infusion pumps. Four months later, subjects returned for repeated perineural catheter insertion and received an ambulatory infusion with the alternate solution ("crossover"). Subjects were followed for up to 1 year. RESULTS: By chance, all three subjects received saline during their initial infusion and reported little change in their PLP. One subject did not receive crossover treatment, but the remaining two subjects reported complete resolution of their PLP during and immediately following treatment with ropivacaine. One subject experienced no PLP recurrence through the 52-week follow-up period and the other reported mild PLP occurring once each week of just a small fraction of his original pain (pretreatment: continuous PLP rated 10/10; posttreatment: no PLP at baseline with average of one PLP episode each week rated 2/10) for 12 weeks (lost to follow-up thereafter). CONCLUSIONS: A prolonged ambulatory CPNB may be a reliable treatment for intractable PLP. The results of this pilot study suggest that a large, randomized clinical trial is warranted. Wiley Periodicals, Inc.
Authors: N Birbaumer; W Lutzenberger; P Montoya; W Larbig; K Unertl; S Töpfner; W Grodd; E Taub; H Flor Journal: J Neurosci Date: 1997-07-15 Impact factor: 6.167
Authors: Robert H Dworkin; Dennis C Turk; Sarah Peirce-Sandner; Ralf Baron; Nicholas Bellamy; Laurie B Burke; Amy Chappell; Kevin Chartier; Charles S Cleeland; Ann Costello; Penney Cowan; Rozalina Dimitrova; Susan Ellenberg; John T Farrar; Jacqueline A French; Ian Gilron; Sharon Hertz; Alejandro R Jadad; Gary W Jay; Jarkko Kalliomäki; Nathaniel P Katz; Robert D Kerns; Donald C Manning; Michael P McDermott; Patrick J McGrath; Arvind Narayana; Linda Porter; Steve Quessy; Bob A Rappaport; Christine Rauschkolb; Bryce B Reeve; Thomas Rhodes; Cristina Sampaio; David M Simpson; Joseph W Stauffer; Gerold Stucki; Jeffrey Tobias; Richard E White; James Witter Journal: Pain Date: 2010-03-06 Impact factor: 6.961
Authors: D M Ehde; J M Czerniecki; D G Smith; K M Campbell; W T Edwards; M P Jensen; L R Robinson Journal: Arch Phys Med Rehabil Date: 2000-08 Impact factor: 3.966
Authors: Brian M Ilfeld; Sarah J Madison; Preetham J Suresh; Navparkash S Sandhu; Nicholas J Kormylo; Nisha Malhotra; Vanessa J Loland; Mark S Wallace; James A Proudfoot; Anya C Morgan; Cindy H Wen; Anne M Wallace Journal: Reg Anesth Pain Med Date: 2014 Mar-Apr Impact factor: 6.288
Authors: Brian M Ilfeld; Rodney A Gabriel; Michael F Saulino; John Chae; P Hunter Peckham; Stuart A Grant; Christopher A Gilmore; Michael C Donohue; Matthew G deBock; Amorn Wongsarnpigoon; Joseph W Boggs Journal: Pain Pract Date: 2016-11-11 Impact factor: 3.183
Authors: V Wylde; J Dennis; A D Beswick; J Bruce; C Eccleston; N Howells; T J Peters; R Gooberman-Hill Journal: Br J Surg Date: 2017-07-06 Impact factor: 6.939
Authors: Brian M Ilfeld; Bahareh Khatibi; Kamal Maheshwari; Sarah J Madison; Wael Ali Sakr Esa; Edward R Mariano; Michael L Kent; Steven Hanling; Daniel I Sessler; James C Eisenach; Steven P Cohen; Edward J Mascha; Chao Ma; Jennifer A Padwal; Alparslan Turan Journal: Pain Date: 2021-03-01 Impact factor: 7.926